IL6 and neoplasm: The IL‐6 receptor inhibitor tocilizumab and IL‐6 antagonist siltuximab have been shown to augment the anti‐tumor activity of chemotherapeutic agents in preclinical trials, and further clinical studies are expected.343, 344